Therapeutics News and Research

RSS

New study explores obecabtagene autoleucel for adults with hard-to-treat leukemia

FELIX study results reveal obe-cel's potential in relapsed B-cell ALL, achieving 77% remission with low severe toxicity, enhancing CAR T-cell therapy outcomes.

2 Dec 2024

Study reveals effects of temporary blood flow loss on blood vessels in hypertensive rats

A study coordinated by Dr Francesc Jiménez-Altayó, researcher at the Institut de Neurociències of the UAB (INc-UAB) and at CIBERCV, shows that temporary lack of blood flow to the brain can lead to lasting changes in the small arteries of the abdomen in rats with high blood pressure.

28 Nov 2024

Obe-cel demonstrates strong efficacy and safety in treating leukemia

Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) who were treated with the novel anti-CD19 chimeric antigen receptor (CAR) T cell therapy, obecabtagene autoleucel (obe-cel), experienced high response rates and most did not need a subsequent stem cell transplant (SCT), according to results from the Phase Ib/II FELIX trial co-led by researchers at The University of Texas MD Anderson Cancer Center.

27 Nov 2024

Novel mRNA-based therapy offers hope for patients with proliferative vitreoretinopathy

A new preclinical study by Mass Eye and Ear investigators showed that a novel mRNA-based therapy may be able to prevent blindness and scarring from proliferative vitreoretinopathy (PVR) following a retinal detachment repair or traumatic injury to the eye.

27 Nov 2024

Stanford team uses natural cell death mechanism to kill cancer cells

Our bodies divest themselves of 60 billion cells every day through a natural process of cell culling and turnover called apoptosis.

27 Nov 2024

Study reveals protein mobility defect as a key factor in chronic diseases

Chronic diseases like type 2 diabetes and inflammatory disorders have a huge impact on humanity. They are a leading cause of disease burden and deaths around the globe, are physically and economically taxing, and the number of people with such diseases is growing.

27 Nov 2024

New insights into cationic polymer structure in RNA drug delivery

LMU researchers have investigated how cationic polymers organize on a molecular level when transporting RNA drugs.

27 Nov 2024

New gold-based drug proves to be more potent than standard chemotherapy

A new gold-based drug can slow tumour growth in animals by 82% and target cancers more selectively than standard chemotherapy drugs, according to a study by Australian and Indian researchers.

27 Nov 2024

MR1 molecule and vitamin B6 could unlock new paths for cancer immunotherapy

Effective immunity hinges on the ability to sense infection and cellular transformation. In humans, there is a specialized molecule on the surface of cells termed MR1.

27 Nov 2024

Irregular sleep may elevate risk of major cardiovascular events

An irregular sleep-wake cycle is associated with a heightened risk of major cardiovascular events, such as heart attack and stroke, even for those who clock up the recommended nightly hours of shut-eye, finds research published online in the Journal of Epidemiology & Community Health.

26 Nov 2024

University of Oklahoma professor honored with prestigious Palade Prize for pancreatic cancer research

Min Li, Ph.D., a George Lynn Cross Professor of Medicine, Surgery and Cell Biology at the University of Oklahoma College of Medicine and Associate Director for Global Oncology at OU Health Stephenson Cancer Center, will receive the 2024 Palade Prize from the International Association of Pancreatology.

26 Nov 2024

GLP-1 receptor agonists prove effective for kidney and cardiovascular outcomes

The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular outcomes shows they have significant benefits in people with and without diabetes.

25 Nov 2024

Revolutionary strategy offers hope for type 1 diabetes treatment

Regenerative medicine holds the extraordinary promise that future patients in need of new cells, tissues or organs will no longer have to rely on donors. Organ shortages and cell type mismatches will become past problems, replaced by safe, on-demand options for anyone who needs a transplant.

25 Nov 2024

Dopamine and serotonin balance reward learning in opposing ways

If you've heard of two of the brain's chemical neurotransmitters, it's probably dopamine and serotonin. Never mind that glutamate and GABA do most of the work - it's the thrill of dopamine as the "pleasure chemical" and serotonin as tender mood-stabilizer that attract all the headlines.

25 Nov 2024

Hamilton and Amabel James Center for AI and Human Health launches at Mount Sinai

Today, the Mount Sinai Health System, one of New York City's largest academic medical systems, announced the opening of the Hamilton and Amabel James Center for Artificial Intelligence and Human Health, which is dedicated to enhancing health care delivery through the research, development, and application of innovative artificial intelligence (AI) tools and technologies.

25 Nov 2024

Steritas announces collaboration with argenx to advance evidence for novel steroid-sparing therapeutics

Steritas LLC., a company dedicated to enhancing care for steroid-treated patients, today announced a licensing agreement with argenx, a global immunology company, for use of its STOX® Suite of steroid-toxicity clinical outcome assessments (COAs) across argenx's development programs for differentiated immunology therapeutics.

From Steritas LLC 25 Nov 2024

Groundbreaking research sheds light on mitochondrial DNA depletion syndrome

Mitochondrial DNA depletion syndrome (MTDPS) is a rare genetic disorder characterized by a marked decrease in mitochondrial DNA (mtDNA).

25 Nov 2024

Asimov and RevOpsis Therapeutics sign licensing agreement for high titer multispecific-expressing cell line

Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced a licensing agreement for its CHO Edge System with RevOpsis Therapeutics ("RevOpsis"), a next-generation biopharmaceutical company spearheading innovation of multispecific biologics in ophthalmic therapies

From Asimov 25 Nov 2024

Enterprise Therapeutics publishes on medicinal chemistry of ETD001, a novel inhaled ENaC blocker for treatment of cystic fibrosis

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of people with respiratory diseases, today announced the publication of a peer reviewed study in The European Journal of Medicinal Chemistry.

From Enterprise Therapeutics Ltd 25 Nov 2024

Researchers develop new approach to effectively deliver therapeutics into the brain

Researchers at the Icahn School of Medicine at Mount Sinai have developed an innovative approach - demonstrated in mouse models and isolated human brain tissue - to safely and effectively deliver therapeutics into the brain, providing new possibilities for treating a wide range of neurological and psychiatric diseases.

25 Nov 2024

Therapeutics News and Research

New study explores obecabtagene autoleucel for adults with hard-to-treat leukemia

Study reveals effects of temporary blood flow loss on blood vessels in hypertensive rats

Obe-cel demonstrates strong efficacy and safety in treating leukemia

Novel mRNA-based therapy offers hope for patients with proliferative vitreoretinopathy

Stanford team uses natural cell death mechanism to kill cancer cells

Study reveals protein mobility defect as a key factor in chronic diseases

New insights into cationic polymer structure in RNA drug delivery

New gold-based drug proves to be more potent than standard chemotherapy

MR1 molecule and vitamin B6 could unlock new paths for cancer immunotherapy

Irregular sleep may elevate risk of major cardiovascular events

University of Oklahoma professor honored with prestigious Palade Prize for pancreatic cancer research

GLP-1 receptor agonists prove effective for kidney and cardiovascular outcomes

Revolutionary strategy offers hope for type 1 diabetes treatment

Dopamine and serotonin balance reward learning in opposing ways

Hamilton and Amabel James Center for AI and Human Health launches at Mount Sinai

Steritas announces collaboration with argenx to advance evidence for novel steroid-sparing therapeutics

Groundbreaking research sheds light on mitochondrial DNA depletion syndrome

Asimov and RevOpsis Therapeutics sign licensing agreement for high titer multispecific-expressing cell line

Enterprise Therapeutics publishes on medicinal chemistry of ETD001, a novel inhaled ENaC blocker for treatment of cystic fibrosis

Researchers develop new approach to effectively deliver therapeutics into the brain

Understanding the DNA Damage Response in Innate Immunity eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News